Current status of adoptive immunotherapy of malignancies

Expert Opinion on Biological Therapy

Volumn 2, Issue 3, 2002, Pages 237-247

  Morse, Michael A ^a   Clay, Timothy M ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Cytotoxic T cells; T cell receptor

Indexed keywords

BCG VACCINE; BRYOSTATIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IONOMYCIN; STAPHYLOCOCCUS ENTEROTOXIN A; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL MODEL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; GLIOMA; HUMAN; INTRAPORTAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE CELL; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MEMORY CELL; MOUSE; MULTICENTER STUDY; NASOPHARYNX CARCINOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PORTAL VEIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; BRAIN NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

ANIMALIA; CYTOMEGALOVIRUS; MYCOBACTERIUM BOVIS BCG; STAPHYLOCOCCUS;

EID: 0036242370     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.3.237     Document Type: Review

References (88)

1. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
2. Adoptive cellular therapy
3. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma
4. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
5. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype
6. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer
7. Adoptive cellular immunotherapy for the treatment of malignant gliomas
8. Immunotherapy of metastatic kidney cancer
9. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer
10. T cells activated in vitro as immunotherapy for renal cell carcinoma: Characterization of 2 effector T-cell populations
11. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma
12. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: Final results from a randomized, controlled, multisite study
13. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients
14. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-Phase I clinical trial
15. Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor
16. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience
17. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
18. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma
19. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience
20. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
21. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells
22. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma
23. T-cell adoptive immunotherapy of metastatic renal cell carcinoma
24. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: A phase 1 study
25. Bryostatin/ ionomycin-activated T cells mediate regression of established tumors
26. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: A pilot clinical trial
27. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompadbility complex class I-negative A9P melanoma
28. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules
29. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
30. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells
31. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation
32. T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance
33. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression
34. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.J
35. T cell adoptive immunotherapy of newly diagnosed gliomas
36. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody
37. Generation of turnor-spechqc C-TLs blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition
38. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells
39. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice
40. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy
41. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells
42. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy
43. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer ofT-cell clones from the donor
44. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
45. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma
46. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2
47. Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma
48. An antigen-targeted approach to adoptive transfer therapy of cancer
49. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
50. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers
51. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion
52. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay
53. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination
54. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lympocytes confers anti-tumor reactivity
55. Immunotherapy through TCR gene transfer
56. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
57. Specific cytotoxic T lymphocytes in gene therapy
58. Human T lymphocyte genetic modification with naked DNA
59. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
60. Targeting of T lymphocytes to Neu/ HER2-expressing cells using chimeric single chain Fv receptors
61. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells
62. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope
63. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lyric capacity
64. Anti-tumor activity of human T cells expressing the cc49-zeta chimeric immune receptor
65. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes
66. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
67. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma
68. Localization of 11 lindium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response
69. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer
70. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial
71. In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients
72. Physiologically based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy
73. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals
74. Local injections of OK432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Th1-rype cytokines and CXC3 chemokines
75. Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein
76. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium
77. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
78. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells
79. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes
80. Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness
81. T-cell-directed cancer vaccines: Mechanisms of immune escape and immune tolerance
82. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
83. Systemic and local immunosuppression in pancreatic cancer patients
84. A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods
85. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo
86. Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets
87. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance
88. Dose-finding based on feasibility and toxicity in T-cell infusion trials